Table 4 Association of MMP-9 protein levels with pathology/clinical characteristics of PTC patients
From: The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer
Variables | Mean ± SD | Percentiles | P value | ||
|---|---|---|---|---|---|
25th | 50th (Median) | 75th | |||
Patients | |||||
 MNG | 218.14 ± 113.74 | 119.57 | 226.51 | 314.39 | 0.004 |
 PTC | 429.60 ± 288.54 | 194.88 | 429.60 | 467.42 | |
Tissues of PTC patients | |||||
 Adjacent non-tumoral | 223.15 ± 137.68 | 107.27 | 223.15 | 268.00 | < 0.001 |
 Tumoral | 429.60 ± 288.54 | 194.88 | 429.60 | 467.42 | |
Age | |||||
 < 45 years | 245.01 ± 258.08 | 90.34 | 116.59 | 259.65 | 0.001 |
 ≥45 years | 570.55 ± 186.12 | 437.51 | 570.55 | 624.80 | |
Sex | |||||
 Male | 276.52 ± 269.39 | 71.92 | 188.94 | 489.00 | 0.986 |
 Female | 310.36 ± 361.46 | 89.21 | 113.30 | 471.37 | |
BRAF V600E mutation | |||||
 BRAF (−) | 256.67 ± 290.37 | 82.77 | 100.19 | 404.35 | 0.233 |
 BRAF (+) | 345.20 ± 380.80 | 104.74 | 179.27 | 505.23 | |
Tumor size | |||||
 < 2 cm | 302.53 ± 322.00 | 77.18 | 112.10 | 637.68 | 0.156 |
 ≥2 cm | 364.04 ± 354.49 | 156.08 | 267.42 | 399.34 | |
TNM Staging | |||||
 I/II | 220.79 ± 220.09 | 85.35 | 116.59 | 257.37 | 0.001 |
 III/IV | 673.65 ± 212.97 | 521.72 | 673.65 | 825.58 | |
Focality Status | |||||
 Unifocal | 193.61 ± 168.46 | 71.15 | 107.25 | 343.48 | 0.595 |
 Multifocality | 350.86 ± 422.68 | 82.34 | 114.49 | 637.95 | |
Extracapsular invasion | |||||
 No | 406.12 ± 217.46 | 243.05 | 406.12 | 480.45 | 0.931 |
 Yes | 500.05 ± 458.36 | 140.32 | 500.05 | 736.08 | |
LNM | |||||
 No | 269.10 ± 259.47 | 98.07 | 209.34 | 283.47 | 0.169 |
 Yes | 351.85 ± 254.60 | 118.68 | 298.94 | 637.68 | |
Lymphovascular invasion | |||||
 No | 196.44 ± 195.59 | 79.04 | 108.42 | 227.12 | 0.036 |
 Yes | 453.35 ± 345.74 | 178.74 | 298.94 | 805.16 | |